Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Reta
trutide

Retatrutide

LY3437943 (Eli Lilly)

~4731 g/mol Molecular Weight
C₂₂₁H₃₄₂N₄₆O₆₈ Formula
Phase 3 Clinical Trials Status

Evidence level: Randomized phase 3 trials and meta-analyses. TRIUMPH-1 randomized 2,339 adults with obesity (NEJM, 2026).

Regulatory status: Not approved by the FDA or the EMA (November 2026). Phase 3 trials are ongoing.

39 amino acids (GLP-1/GIP/glucagon receptor triple agonist)
Updated on November 17, 2026
Retatrutide Photo: Artem Podrez
Retatrutide Results: What the Trials Really ShowEnglish, subtitles FR · ES · DE · IT · PT

What Is Retatrutide?

Retatrutide, known during development as LY3437943, is an investigational peptide therapeutic developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It belongs to a class of incretin-based medicines but goes a step beyond its predecessors: rather than acting on one or two hormone receptors, it is engineered to activate three simultaneously. For this reason it is often described as a triple agonist or a triple-hormone-receptor agonist.

The molecule is a synthetic, single-chain peptide modified with a fatty-acid side chain that extends its half-life, allowing once-weekly subcutaneous injection. Structurally it builds on the design philosophy of earlier incretin mimetics (the same family that includes semaglutide and tirzepatide) but adds activity at the glucagon receptor, a target historically associated with raising blood sugar rather than lowering it. Reconciling that apparent paradox is central to understanding why the drug works, a point we explore in the mechanism section below.

Retatrutide first entered human testing around 2020, with first-in-human pharmacokinetic data published in 2022. Since then it has generated considerable scientific and public interest, largely because of the magnitude of weight loss observed in mid-stage trials. To place it in context, readers new to this drug class may find our overview of GLP-1 receptor agonists a useful starting point, and our introduction to peptides helpful for the underlying biochemistry.

It is important to state at the outset that retatrutide is not approved for human use by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory body. All of the data discussed in this guide come from clinical research conducted under regulated trial conditions. This article is for educational purposes only and is not medical advice; anyone considering treatment for obesity or diabetes should consult a qualified healthcare professional.

Outside clinical trials, retatrutide also circulates in Europe as a research pre-filled pen. Our explainer on pen and vial formats compares price per mg and stability; it does not change the compound's investigational status.

How Does the Triple Agonist Mechanism Work?

Retatrutide simultaneously stimulates three receptors involved in metabolic regulation: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. Each contributes to weight and glucose control through a distinct pathway, and the central hypothesis is that combining them produces complementary, additive effects.

The GLP-1 component is the most familiar. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion, and acts on appetite centers in the hypothalamus to reduce hunger and food intake. This is the same mechanism that underpins semaglutide. The GIP component also stimulates insulin secretion and appears to improve the way the body handles dietary fat and to modulate appetite signaling in the brain. Its addition is what made tirzepatide more effective than GLP-1 monotherapy.

The glucagon component is the novel and counterintuitive element. Glucagon is best known for raising blood sugar by promoting hepatic glucose output, which would seem undesirable in a diabetes drug. However, glucagon also increases energy expenditure (the rate at which the body burns calories), promotes the breakdown of stored fat (lipolysis), and reduces fat accumulation in the liver. In retatrutide, the glucose-raising tendency of glucagon is counterbalanced by the strong insulin-promoting and appetite-suppressing effects of the GLP-1 and GIP components, so the net result is weight loss and improved glycemic control rather than hyperglycemia.

Preclinical characterization of the molecule, published by Coskun and colleagues in Cell Metabolism in 2022, demonstrated balanced activity across all three receptors and robust reductions in body weight and food intake in animal models. The practical consequence is that retatrutide is theorized to address weight loss from two directions at once: reducing calories taken in (appetite suppression) while potentially increasing calories burned (thermogenesis via glucagon), a combination not available with current dual or single agonists.

What Did the Phase 2 Trials Show?

The most influential dataset is the Phase 2 obesity trial led by Ania Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. This randomized, double-blind, placebo-controlled study enrolled 338 adults with obesity (or overweight with a weight-related condition) and followed them for 48 weeks across several dose levels, with gradual dose escalation to limit side effects.

The headline finding was the scale of weight reduction. At the highest dose (12 mg weekly), participants lost on average approximately 24% of their body weight at 48 weeks, compared with roughly 2% in the placebo group. Lower doses also produced substantial results: about 22.8% at 8 mg and 17.1% at 4 mg (17.3% at 8 mg at the 24-week primary end point). Critically, the weight-loss curve had not clearly plateaued by the end of the 48-week period, raising the possibility that longer treatment could yield even greater reductions. Roughly a quarter of participants on the highest dose achieved at least 30% weight loss, a threshold approaching that of bariatric surgery.

Dose (weekly)Approx. mean weight loss at 48 weeks
Placebo~2%
4 mg~17%
8 mg~22.8%
12 mg~24%

A parallel Phase 2 type 2 diabetes trial, led by Julio Rosenstock and published in The Lancet in 2023, evaluated retatrutide in people with diabetes. It showed meaningful reductions in HbA1c (a marker of long-term blood glucose) along with significant weight loss, supporting the drug's dual potential in both obesity and diabetes. Beyond the primary endpoints, exploratory analyses pointed to improvements in blood pressure, lipid profiles, and markers of liver fat.

These results are genuinely notable, but they should be read with appropriate caution. Phase 2 trials are relatively small and of limited duration; they establish proof of concept rather than definitive efficacy or long-term safety. The larger and longer Phase 3 program is designed to confirm whether these effects hold up across thousands of patients and to characterize rarer adverse events. For context on how peptide candidates progress through testing, see our peptide glossary.

Phase 3 results (TRIUMPH program)

Between December 2025 and November 2026, Eli Lilly reported the first phase 3 results for retatrutide. All trials randomized adults to once-weekly retatrutide or placebo, alongside diet and physical activity, with a gradual step-up from a low starting level. Two analyses are reported: the treatment-regimen estimand counts everyone randomized, including people who stopped treatment; the efficacy estimand estimates the effect in people who stayed on treatment and gives higher numbers.

TrialPopulationDurationMean weight change, highest arm vs placebo
TRIUMPH-4 (topline, December 2025)Obesity or overweight with knee osteoarthritis, no diabetes68 weeks-28.7% vs -2.1% (efficacy); -23.7% vs -4.6% (treatment-regimen)
TRIUMPH-1 (NEJM, 2026; 2,339 adults)Obesity or overweight, no diabetes80 weeks-25.0% vs -3.9% (treatment-regimen); -28.3% (efficacy)
TRIUMPH-2 (Lancet, 2026; 1,152 adults)Obesity or overweight with type 2 diabetes80 weeks-18.8% vs -5.1% (treatment-regimen); -20.8% (efficacy)
TRIUMPH-3 (topline, July 2026; 1,949 adults)BMI 35 or more with established cardiovascular disease80 weeks-22.6% vs -3.2% (efficacy)

Beyond weight. In TRIUMPH-4, knee pain on the WOMAC scale fell by up to 4.5 points versus 2.4 points with placebo. TRIUMPH-1 also met its primary end points for knee osteoarthritis pain and for the apnea-hypopnea index in participants with obstructive sleep apnea. In TRIUMPH-2, HbA1c fell by 1.4 to 1.6 percentage points from a baseline of 7.7%, versus 0.2 with placebo.

Safety. Gastrointestinal events (nausea, diarrhea, constipation, vomiting) were the most common adverse events and increased with the treatment level. Dysesthesia (abnormal or unpleasant skin sensations) was reported more often than with placebo: up to 20.9% versus 0.7% in TRIUMPH-4 and about 6% versus 1% in TRIUMPH-3. Discontinuation because of adverse events reached 18.2% in the highest arm of TRIUMPH-4 and 13.5% in TRIUMPH-3, versus about 4% to 5% with placebo. TRIUMPH-3 was not designed as a cardiovascular outcomes trial, and its number of major cardiovascular events was too small for a conclusion.

Next steps. Lilly states that it plans to submit retatrutide to the FDA in the first quarter of 2027. Lilly and the FDA disagree in court on whether retatrutide should be reviewed as a biologic, which determines the type of application. Until a regulator approves it, retatrutide remains an investigational drug. Retatrutide is not covered by the US HHS enforcement-discretion policy of 28 October 2026, which concerns six other peptides (BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV).

How Does Retatrutide Compare to Tirzepatide?

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management) is also an Eli Lilly product and is currently the benchmark for incretin-based weight loss. The key structural difference is the number of receptors targeted: tirzepatide is a dual agonist (GLP-1 and GIP), whereas retatrutide is a triple agonist that adds glucagon receptor activity. That third target is the central reason researchers expect retatrutide to push weight loss further.

On efficacy, the contrast is striking, though it must be framed carefully. In its pivotal SURMOUNT obesity trials, tirzepatide produced average weight loss of roughly 20-22% over 72 weeks. Retatrutide's Phase 2 trial reported around 24%, but over a shorter 48 weeks and in a smaller population. Because these figures come from separate trials with different designs, durations, and patient groups, they cannot be compared head-to-head with any precision. Only a direct comparative trial could establish true superiority, and none has yet been published.

TirzepatideRetatrutide
Receptor targetsGLP-1 + GIP (dual)GLP-1 + GIP + glucagon (triple)
DeveloperEli LillyEli Lilly
DosingOnce weekly, subcutaneousOnce weekly, subcutaneous
Approval statusFDA-approved (2022 diabetes, 2023 obesity)Investigational (Phase 3)
Reported weight loss~20-22% (SURMOUNT, 72 wk)~24% (Phase 2, 48 wk)

The added glucagon activity may also confer advantages beyond the scale, particularly for liver fat reduction and energy expenditure. Early data suggest retatrutide is especially effective at clearing fat from the liver, which has implications for metabolic liver disease (discussed below). On the other hand, the glucagon component requires careful dosing to avoid unwanted increases in blood glucose or heart rate, and the longer safety record of tirzepatide remains an advantage for an approved, real-world product.

For now, the most accurate summary is that retatrutide is a promising next-generation candidate that may eventually exceed tirzepatide on weight loss, but that conclusion is not yet established by direct evidence. Tirzepatide remains an approved, available option, while retatrutide is still in clinical development.

What Are the Side Effects and Safety Profile?

Consistent with the broader incretin drug class, the most common adverse effects of retatrutide in trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These events were generally mild to moderate, occurred most often during dose escalation, and tended to diminish over time. Their frequency and intensity were clearly dose-dependent, which is precisely why trial protocols escalate the dose gradually rather than starting at the target level.

A distinctive observation linked to the glucagon component was a modest, dose-dependent increase in heart rate, on the order of several beats per minute on average. Researchers are monitoring the cardiovascular implications of this finding closely, as it differs somewhat from the profile of pure GLP-1 or dual agonists. Transient increases in certain laboratory markers were also noted in some participants and will require continued surveillance in larger studies.

Because retatrutide is still investigational, its long-term safety profile is not fully characterized. Rare but serious risks associated with the incretin class (such as pancreatitis, gallbladder disease, and the theoretical thyroid C-cell tumor signal seen in rodents with some GLP-1 drugs) cannot be ruled out and are specifically being evaluated in the ongoing Phase 3 program. Drugs in this class generally carry a contraindication warning regarding personal or family history of medullary thyroid carcinoma.

It is also worth noting the practical safety concern around unregulated sources. Because retatrutide is not approved, any product sold to consumers outside of a clinical trial is, by definition, not manufactured, tested, or dosed under regulatory oversight. Purity, sterility, and actual content cannot be verified, which introduces risks entirely separate from those of the molecule itself. This information is educational and not a recommendation to use retatrutide. Anyone with questions about obesity or diabetes treatment should consult a healthcare professional and review our medical disclaimer.

What Conditions Could Retatrutide Treat?

While obesity and type 2 diabetes are the primary targets, retatrutide's triple mechanism has prompted research into several adjacent metabolic conditions. The most advanced of these is metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), and its more severe inflammatory form, MASH.

A Phase 2 substudy published in Nature Medicine in 2024 reported that retatrutide produced substantial reductions in liver fat content, with a large proportion of participants achieving normalization of liver fat by the end of the treatment period. This effect is biologically plausible: the glucagon component directly promotes hepatic fat metabolism, which may give retatrutide an edge in liver-focused indications relative to GLP-1-only therapies. Because MASLD affects a significant share of people with obesity and currently has limited pharmacological options, this is an area of considerable interest.

Researchers have also explored potential benefits for cardiovascular and renal risk factors, given that weight loss and improved glycemic control typically translate into better blood pressure, lipids, and kidney markers. Exploratory trial data have shown movement in these parameters, but dedicated cardiovascular outcome trials (the gold standard for proving such benefits) would be needed to make any firm claims. A trial examining retatrutide in osteoarthritis of the knee, where weight is a contributing factor, has also been part of the broader program.

It bears repeating that none of these uses is approved, and the supporting data remain early-stage. Distinguishing genuine, replicated clinical findings from preliminary signals is essential when evaluating any investigational compound. The breadth of conditions under study reflects the drug's metabolic versatility, but breadth of investigation is not the same as proven efficacy. Readers interested in how combination approaches are evaluated may also find our article on peptide stacking contextually useful, while bearing in mind it addresses a different category of compounds.

What Is the FDA Approval Timeline?

As of November 2026, retatrutide is completing Phase 3 clinical development under Eli Lilly's TRIUMPH program, a series of large, long-duration trials evaluating its safety and efficacy across obesity, type 2 diabetes, and related conditions such as MASH and knee osteoarthritis. Phase 3 is the final and most rigorous stage before a company can submit a marketing application to regulators.

The general regulatory pathway proceeds in steps: completion of Phase 3 trials, analysis and publication of results, submission of a New Drug Application (NDA) to the FDA, and then a review period during which the agency evaluates the full data package. Each stage takes time, and timelines frequently shift depending on trial enrollment, data readouts, and regulatory questions.

StageStatus (November 2026)
Phase 1 (first-in-human)Completed (data published 2022)
Phase 2 (obesity & diabetes)Completed (data published 2023)
Phase 3 (TRIUMPH program)First results reported December 2025 to November 2026; other trials ongoing
FDA submission & reviewNot yet filed; Lilly plans submission in Q1 2027

With a submission planned for the first quarter of 2027 and an FDA review that usually takes about a year for a new molecule, a potential FDA decision is not expected before late 2027 at the earliest, and possibly later. Any specific date should be treated as an estimate rather than a commitment; only Eli Lilly's official announcements and FDA filings provide authoritative timelines. Approval is never guaranteed. A drug can perform well in Phase 2 yet fail to meet endpoints or raise safety concerns in Phase 3.

For prospective patients, the practical takeaway is that retatrutide will not be available by prescription until it clears these hurdles. Until then, it exists solely as an investigational compound, and the only legitimate way to receive it is through enrollment in an authorized clinical trial.

Test your knowledge

Quick quiz · 6 questions

Retatrutide: all our articles

Frequently Asked Questions

What is retatrutide used for?
Retatrutide is being investigated primarily for the treatment of obesity and type 2 diabetes, with additional research into metabolic liver disease (MASLD/MASH) and related conditions. However, it is not currently approved for any use and remains in clinical trials. It is not available by prescription.
How is retatrutide different from semaglutide and tirzepatide?
Semaglutide acts on a single receptor (GLP-1), tirzepatide acts on two (GLP-1 and GIP), and retatrutide acts on three (GLP-1, GIP, and glucagon). The added glucagon activity is thought to increase energy expenditure and reduce liver fat, which may translate into greater weight loss, though this has not been confirmed in a direct head-to-head trial.
How much weight can you lose on retatrutide?
In a 48-week Phase 2 trial, participants on the highest dose (12 mg weekly) lost an average of approximately 24% of their body weight, with about a quarter losing 30% or more. In the larger phase 3 TRIUMPH-1 trial (80 weeks), mean weight loss in the highest arm was 25.0% versus 3.9% with placebo (treatment-regimen estimand, which counts everyone randomized; 28.3% in Lilly's efficacy estimand). These are trial averages, not guaranteed outcomes.
Is retatrutide FDA approved?
No. Retatrutide is an investigational drug that has not been approved by the FDA, the EMA, or any other regulatory agency. Its Phase 3 trials have reported positive results, Lilly plans to submit it to the FDA in the first quarter of 2027, and a decision is not expected before late 2027 at the earliest. Approval is not guaranteed.
What are the main side effects of retatrutide?
The most common side effects in trials were gastrointestinal (nausea, vomiting, diarrhea, and constipation), which were generally mild to moderate, dose-dependent, and most frequent during dose escalation. A modest increase in heart rate was also observed, likely related to the glucagon component. Long-term safety is still being studied.
When will retatrutide be available?
Retatrutide is still in Phase 3 development and is not yet available by prescription. Eli Lilly plans to submit it to the FDA in the first quarter of 2027. After review, a potential launch, if approved, would not occur before late 2027 and possibly later. Official timelines come only from the manufacturer and the FDA.
Why does retatrutide include a glucagon receptor agonist if glucagon raises blood sugar?
Although glucagon can raise blood sugar, it also increases energy expenditure, promotes fat breakdown, and reduces liver fat. In retatrutide, the glucose-raising tendency is offset by the strong insulin-promoting and appetite-suppressing effects of the GLP-1 and GIP components, so the overall result is weight loss and improved glucose control rather than higher blood sugar.
Is it safe to buy retatrutide online as a research peptide?
No. Retatrutide is not approved for human use, and products sold online as "research peptides" are not manufactured, tested, or dosed under regulatory oversight. Purity, sterility, and accurate content cannot be verified, and self-administration of an investigational injectable carries serious legal and health risks. Consult a licensed healthcare professional about approved options.

Sources

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. (PubMed)
  2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. (PubMed)
  3. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. (PubMed)
  4. Sanyal AJ, Kaplan LM, Frias JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. (PubMed)
  5. Urva S, Coskun T, Loh MT, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. (PubMed)
  6. Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). New England Journal of Medicine. (PubMed)
  7. Bellido V, le Roux CW, Ekinci EI, et al. (2026). Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. (PubMed)
  8. Grunstein RR, Somers VK, Azarbarzin A, et al. (2026). Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. New England Journal of Medicine. (PubMed)
  9. Eli Lilly and Company (2025). Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release (PRNewswire). (biospace.com)
  10. Eli Lilly and Company (2026). Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). Press release (PRNewswire). (biospace.com)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer

Retatrutide
Retatrutide
Discover →